Endogenous peptidergic modulation of perisynaptic Schwann cells at the frog neuromuscular junction.
1. Although peptides are important modulators of synapses, their action on synapse-glia interactions remain unclear. The amphibian neuromuscular junction (NMJ) was used to examine the effects of substance P (SP) on perisynaptic Schwann cells (PSCs), glial cells at the frog NMJ, by monitoring changes in intracellular Ca2+. 2. SP induced Ca2+ responses that were mimicked by the neurokinin 1 receptor (NK-1) agonist septide and with a shorter delay by the SP fragment, SP(6-11). SP and SP(6-11) responses were blocked by NK-1 antagonists SR140333 and LY303870. 3. Ca2+ responses remained unchanged when extracellular Ca2+ was removed but were blocked after pertussis toxin (PTX) treatment, indicating that the receptors were linked to internal stores of Ca2+ via a PTX-sensitive G-protein. 4. The slowly hydrolysable NK-1 agonist [Sar9, Met(O2)11]-SP only induced Ca2+ responses when applied for a long period of time and not during brief, local applications, suggesting the involvement of SP hydrolysis. Acetylcholinesterase (AChE) may not be involved in SP degradation since Ca2+ responses evoked by SP were unchanged in the presence of the cholinesterase inhibitor neostigmine. 5. Ca2+ responses induced by muscarine and nerve stimulations were almost abolished when preceded by SP applications, while those induced by ATP were significantly reduced. The rundown of the nerve-evoked Ca2+ responses in PSCs was attenuated in the presence of SR140333. 6. These results indicate that endogenous SP is involved in the regulation of PSC activity and that SP is an important modulator of glial cell Ca2+ signalling and synapse-glia communication.
Bourque
M J
MJ
Centre de Recherche en Sciences Neurologiques and Departement de physiologie, Universite de Montreal, Montreal, Canada H3C 3J7.
Robitaille
R
R
D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D002118:Calcium / Q000378:metabolism; D019204:GTP-Binding Proteins / Q000378:metabolism; D009116:Muscarine / Q000494:pharmacology; D018482:Muscle, Skeletal / Q000294:innervation*; D009388:Neostigmine / Q000494:pharmacology; D064729:Neurokinin-1 Receptor Antagonists; D009469:Neuromuscular Junction / Q000187:drug effects / Q000502:physiology*; D010446:Peptide Fragments / Q000494:pharmacology; D037342:Pertussis Toxin; D010880:Piperidines / Q000494:pharmacology; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives; D011812:Quinuclidines / Q000494:pharmacology; D011894:Rana pipiens; D018040:Receptors, Neurokinin-1 / Q000819:agonists; D012583:Schwann Cells / Q000187:drug effects / Q000502:physiology*; D013373:Substance P / Q000031:analogs & derivatives / Q000494:pharmacology* / Q000502:physiology; D013569:Synapses / Q000187:drug effects / Q000502:physiology*; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments; D010880:Piperidines; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; D010566:Virulence Factors, Bordetella; C085215:SR 140333; D013373:Substance P; D009388:Neostigmine; C032292:substance P (6-11); C054725:septide; D009116:Muscarine; D037342:Pertussis Toxin; D000110:Acetylcholinesterase; D019204:GTP-Binding Proteins; D002118:Calcium; D011761:Pyrrolidonecarboxylic Acid